Eli Lilly CFO Anat Ashkenazi resigns; to leave in July 2024

ELI LILLY & Co

Anat Ashkenazi resigns as EVP and CFO to pursue a career opportunity outside the pharmaceutical industry.
She will continue in her role at full capacity and on the Executive Committee through July 2024.
An internal and external search for her successor is actively underway.
Ashkenazi served 23 years at Lilly, with 3 years as CFO overseeing growth.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Anat Ashkenazi

Executive Vice President and Chief Financial Officer

LLY · ELI LILLY & Co

Filed: June 5, 2024, 7:59 PM ET

Anat Ashkenazi resigned as Executive Vice President and Chief Financial Officer of the Company to pursue another career opportunity outside of the pharmaceutical industry.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anat Ashkenazi resigned as Executive Vice President and Chief Financial Officer at ELI LILLY & Co.

Action: resigned
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

Anat Ashkenazi resigned as Executive Vice President and Chief Financial Officer of the Company to pursue another career opportunity outside of the pharmaceutical industry.

View on SEC.gov

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-24-000146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.